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1684-1182/Copyright ª 2015, TaiwanAbstract Background: Invasive candidiasis (IC) is the most common cause of invasive fungal
infections. Identification of risk factors for such infection may help in the empirical therapeu-
tic decision-making process. We conducted this study to characterize the clinical epidemiology
of such infection and to differentiate risk factors between Candida albicans and Candida non-
albicans species.
Methods: We retrospectively evaluated patients with IC from 2011 to 2013. Clinical data, anti-
biotic therapy, underlying condition, and invasive procedures were analyzed and compared be-
tween C. albicans and C. non-albicans species.
Results: C. albicans was the most frequently isolated Candida species (48.6% of all IC pa-
tients), although C. non-albicans spp. were more commonly isolated overall. C. albicans,
Candida tropicalis, and Candida parapsilosis have a high susceptibility rate to all antifungal
agents (>90%), whereas Candida glabrata showed decreased susceptibility to fluconazole
and itraconazole. Amphotericin B demonstrated excellent antifungal activity against all
Candida species. Univariate analyses showed that IC patients with C. albicans had a higher ra-
tio of older age (p Z 0.008), solid tumor (p Z 0.029), and hypoproteinemia (p Z 0.019),
whereas those with C. non-albicans spp. had a higher ratio of hospital length of stay
(p Z 0.005), usage of corticosteroids (p Z 0.011), duration on corticosteroids (p Z 0.005),
chemotherapy (p Z 0.022), hematologic malignancy (p Z 0.039), neutropenia (p Z 0.030),
and usage of glycopeptides (pZ 0.002). Multivariate analyses showed that a significant predic-
tor of IC due to C. albicans was hypoproteinemia [odds ratio (95% confidence interval)Z 2.133
(1.164e3.908), p Z 0.014].t of Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, No. 1
ngqing, China.
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tween C. albicans and C. non-albicans species are different.
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Fungi have emerged as a major cause of human disease
since the early 1980s, especially among patients with
immunocompromised and serious underlying disease.1e4
Invasive fungal infections seriously threaten the health of
hospitalized patients, causing substantial morbidity, mor-
tality, and increases in hospital costs.5,6 Invasive candidi-
asis (IC) is the most common cause of invasive fungal
infections, accounting for 70e90% of all invasive myco-
ses.7,8 Candidemia is the fourth leading cause of blood-
stream infection in the USA.9 Thus, IC has a significant
influence on patient outcomes and the health care econ-
omy.10 It is clear that IC has emerged as an important public
health problem.5,11
Although Candida albicans was the predominant species
in a majority of countries, the proportion of Candida non-
albicans species has increased rapidly in IC patients
recently.12 This change has been attributed to the
increasing use of azole antifungals and invasive pro-
cedures.12 There are remarkable geographical differences
in the epidemiology of Candida infection.13 C. albicans
accounts for 50e70% of Candida infection in the USA,
whereas C. non-albicans species are more common in Asia,
South America, and southern Europe.14,15 Thus, knowledge
of recent, local epidemiological patterns, and susceptibility
to antifungals is of great importance.5
The purpose of this study is to describe the current
epidemiology, antifungal susceptibility to Candida, and the
differences in risk factors between C. albicans and C. non-
albicans species for IC in southwest China. We believe that
the data obtained from this study will help develop clinical
practice recommendations to improve the management
and outcomes of such cases.Methods
Study design and patients
We performed a retrospective study in the First Affiliated
Hospital of Chongqing Medical University, a teaching facility
in southwest China. All Candida species isolated from
blood, other sterile body fluids (including ascitic fluid,
drainage fluid, cerebrospinal fluid, and bile), catheters,
and pus from patients with Candida infection in different
wards from January 2011 to December 2013 were included
in this study. However, Candida strains from sputum and
urine were excluded. For patients with more than one IC
episode, only the first episode was included. All patients
gave informed consent.S, et al., Epidemiology, antifunga
hwest China, Journal of MicrobioloClinical data [including age, sex, hospital length of stay,
patient source, 30-day mortality, all-cause in-hospital
mortality, intensive care unit (ICU) stay, and length of ICU
stay] of patients with invasive Candida infection were
recorded on standardized forms. Antibiotic therapy, un-
derlying condition [including diabetes mellitus, organ
dysfunction, solid tumor, hematologic malignancy, hypo-
proteinemia (serum total protein < 60 g/L or
albumin <25 g/L), severe anemia (hemoglobin <60 g/L),
and neutropenia (absolute neutrophil count < 500 cells/
mL)], and invasive procedures within prior 4 weeks
(including blood product transfusion, hemodialysis, me-
chanical ventilation, tracheal intubation, indwelling gastric
tube, urinary catheter, drainage tube, enema, total
parental nutrition, arterial catheter, central venous cath-
eter, and surgery) were also recorded.
Antifungal susceptibility testing
The susceptibility of 257 Candida strains to five antifungal
agents (amphotericin B, flucytosine, fluconazole, itraco-
nazole, and voriconazole) was tested in vitro using ATB
FUNGUS 3 system (bioMe´rieux, La Balme-les Grottes,
France). For quality control, C. albicans isolates (ATCC
64548) were used. The results were interpreted using the
Clinical and Laboratory Standards Institute M27-A3 micro-
broth dilution method.
Statistical analysis
Data were analyzed using SPSS software version 21.0 (SPSS
Inc., Chicago, IL, USA). The comparison of risk factors be-
tween C. albicans and C. non-albicans species for IC was
performed using univariate analysis followed by multivar-
iate regression. Univariate analysis was performed using
the Chi-square test or Fisher’s exact test for categorical
variables and the ManneWhitney U test for numerical var-
iables. Each risk factor with a p < 0.05 on univariate
analysis was examined further using multivariate logistic
regression. A p value < 0.05 was considered significant.
Results
Patient characteristics and distribution of Candida
A total of 297 nonrepeatable episodes of invasive fungi in-
fections were detected from January 2011 to December
2013, of which 257 (86.5%) IC patients were enrolled in this
study according to the diagnostic criteria of IC.16 Patients
included 170 (66.1%) males and 87 (33.9%) females. The
mean age was 59.15  17.81 years, and 145 patients werel susceptibilities, and risk factors for invasive candidiasis from 2011
gy, Immunology and Infection (2015), http://dx.doi.org/10.1016/
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were responsible for 48.6% (125 of 257) and 51.4% (132 of
257) of IC cases, respectively. The C. non-albicans spp.
isolated included 45 (17.5%) Candida tropicalis, 42 (16.3%)
Candida parapsilosis, 33 (12.8%) Candida glabrata, four
(1.6%) Candida krusei, three (1.2%) Candida sake, two
(0.8%) Candida dubliniensis, two (0.8%) Candida guillier-
mondii, and one (0.4%) Candida intermedia.
The distribution of these 257 IC specimens was as fol-
lows: 93 (36.2%) blood, 29 (11.3%) ascitic fluid, 29 (11.3%)
catheters, 18 (7.0%) drainage fluid, 13 (5.1%) pus, nine
(3.5%) cerebrospinal fluid, eight (3.1%) bile, six (2.3%) vit-
reous body, six (2.3%) puncture fluid, six (2.3%) exudate,
five (1.9%) pleural fluid, and 35 (13.6%) specimens in other
normally sterile sites. The most frequent wards were the
ICUs (31.1%, 80 of 257), the gastrointestinal surgery (15.6%,
40 of 257), the hepatobiliary surgery (10.1%, 26 of 257), the
urinary surgery (5.8%, 15 of 257), and the neurosurgery
(5.1%, 13 of 257) wards.
Susceptibility of Candida isolates to antifungal
drugs
The in vitro susceptibility results of the 257 Candida iso-
lates to five antifungal agents are presented in Table 1.
C. albicans, C. tropicalis, and C. parapsilosis had a high
susceptibility to all the antifungal agents, whereasTable 1 In vitro susceptibility data of Candida spp
Species (No.) Antifungal agent
Range
Candida albicans (125) Amphotericin B 0.5 to 1
Flucytosine 0.062 to >
Fluconazole 0.125 to 8
Itraconazole 0.062 to 4
Voriconazole 0.062 to >
Candida tropicalis (45) Amphotericin B 0.5 to 1
Flucytosine 0.062 to 4
Fluconazole 0.25 to >12
Itraconazole 0.062 to 4
Voriconazole 0.062 to 0
Candida parapsilosis (42) Amphotericin B 0.5 to 2
Flucytosine 0.062 to 4
Fluconazole 0.25 to 4
Itraconazole 0.062 to 1
Voriconazole 0.062 to 0
Candida glabrata (33) Amphotericin B 0.5 to 1
Flucytosine 0.062 to >
Fluconazole 0.25 to >12
Itraconazole 0.125 to >8
Voriconazole 0.062 to >
Othersa (12) Amphotericin B 0.5 to 1
Flucytosine 0.062 to 8
Fluconazole 0.5 to 64
Itraconazole 0.062 to >
Voriconazole 0.062 to 0
a Others include Candida krusei (n Z 4), Candida sake (n Z 3), Ca
Candida intermedia (n Z 1).
MIC Z minimum inhibitory concentration; R Z resistant; S Z suscep
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j.jmii.2015.01.005C. glabrata showed a low susceptibility (only 54.5%) to
fluconazole and itraconazole. Amphotericin B demon-
strated excellent antifungal activity against all Candida
species.
Mortality rate of patients with IC
Among patients with IC, the 30-day mortality rate was 9.7%
(25 of 257). The 30-day mortality rates of C. albicans and C.
non-albicans were 8.0% (10 of 125) and 11.4% (15 of 132),
respectively (Table 2). The respective 30-day mortality
rates among C. non-albicans were as follows (Table 2): C.
tropicalis, 15.6% (7/45); C. parapsilosis, 14.3% (6/42); C.
glabrata, 3.0% (3/33); and others, 8.3% (1/12). Patients
with C. tropicalis IC had the highest rate of 30-day mor-
tality, whereas those with C. glabrata IC had the lowest
mortality rate. The all-cause in-hospital mortality was
14.4% (37/257). The all-cause in-hospital mortality rates of
IC patients with each Candida species were demonstrated
in Table 2.
Risk factors for C. albicans ICs compared with C.
non-albicans ICs
Univariate analyses showed a significant difference be-
tween patients with C. albicans and patients infected with
C. non-albicans spp. with regard to age, hospital length ofMIC (mg/mL) %
50% 90% S SDD R
0.5 0.5 100 0
16 0.125 0.25 97.6 2.4
0.25 0.5 97.6 2.4
0.062 0.125 93.6 6.4
8 0.062 0.062 94.4 5.6
0.5 1 100 0
0.125 0.125 100 0
8 1 2 97.8 2.2
0.125 0.25 100 0
.125 0.062 0.125 100 0
0.5 1 100 0
0.125 0.25 100 0
0.5 2 97.6 2.4
0.125 0.25 97.6 2.4
.125 0.062 0.062 100 0
0.5 1 100 0
16 0.125 0.5 97.0 3.0
8 8 32 54.5 31.8 13.7
2 4 54.5 45.5
8 0.25 0.5 90.9 9.1
0.5 1 100 0
0.25 1 75.0 25.0
8 32 50.0 50.0
8 0.5 2 50.0 50.0
.5 0.25 0.5 100 0
ndida dubliniensis (n Z 2), Candida guilliermondii (n Z 2), and
tible; SDD Z dose-dependent susceptible.
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Table 2 Mortality rate of different species
Species (No.) 30-d mortality (n Z 25) All-cause in-hospital mortality
(n Z 37)
n (%) % mortality
in species
n (%) % mortality
in species
Candida albicans (125) 10 (40.0) 8.0 17 (45.9) 13.6
Candida non-albicans (132) 15 (60.0) 11.4 20 (54.1) 15.2
Candida tropicalis (45) 7 (28.0) 15.6 9 (24.3) 20.0
Candida parapsilosis (42) 6 (24.0) 14.3 7 (18.9) 16.7
Candida glabrata (33) 1 (4.0) 3.0 3 (8.1) 9.1
Othersa (12) 1 (4.0) 8.3 1 (2.7) 8.3
a Others include Candida krusei (n Z 4), Candida sake (n Z 3), Candida dubliniensis (n Z 2), Candida guilliermondii (n Z 2), and
Candida intermedia (n Z 1).
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chemotherapy, solid tumor, hematologic malignancy,
hypoproteinemia, neutropenia, and usage of glycopeptides.
A comparison between C. albicans and C. non-albicans spp.
demonstrated that IC patients with C. albicans had a higher
ratio of older age (pZ 0.008), solid tumor (pZ 0.029), and
hypoproteinemia (p Z 0.019), whereas those with C. non-
albicans spp. had a higher ratio of hospital length of stay
(pZ 0.005), usage of corticosteroids (pZ 0.011), duration
on corticosteroids (pZ 0.005), chemotherapy (pZ 0.022),
hematologic malignancy (p Z 0.039), neutropenia
(p Z 0.030), and usage of glycopeptides (p Z 0.002; Table
3). Multivariate analyses showed that a significant predictor
for IC due to C. albicans was hypoproteinemia [odds ratio
(95% confidence interval) Z 2.133 (1.164e3.908),
p Z 0.014; Table 4].Discussion
The epidemiology and antifungal susceptibility of invasive
Candida infections in different wards are scarcely defined
in China. Our study described the distribution, in vitro
antifungal susceptibility, and the difference of risk factors
between C. albicans and C. non-albicans spp. infection
from January 2011 to December 2013 in southwest China.
In our study, invasive Candida infection is the most
common invasive fungal infection, accounting for 86.5%
(257 of 297) of all invasive mycoses, in accordance with
reports by Lamagni et al.7,8 Although C. albicans was the
most common Candida species, C. non-albicans spp. are
increasing in frequency in China17 and worldwide.18 This
may be due to surgery, aging of population, and the
increasing use of low-cost azoles.13 In this study, C. albicans
was the most frequently isolated Candida species (48.6% of
all IC patients), although C. non-albicans spp. were more
commonly isolated overall. C. tropicalis, C. parapsilosis,
and C. glabrata were the most common strains among C.
non-albicans spp., which concurs with the report of Vincent
et al.19
In our study, patients infected with C. albicans, C. tro-
picalis, and C. parapsilosis had a high susceptibility rate to
the five antifungal agents (>90%). There were consistent
findings in some previous reports, which suggested that
azole resistance was uncommon in C. albicans, C.Please cite this article in press as: Pu S, et al., Epidemiology, antifunga
to 2013 in a teaching hospital in southwest China, Journal of Microbiolo
j.jmii.2015.01.005parapsilosis, and C. tropicalis (<10%).18,20 Resistance to
fluconazole and itraconazole was more common in other C.
non-albicans spp. (such as C. glabrata, C. krusei, and C.
guilliermondii), implying that these antifungal agents
should not be used in IC patients with these C. non-albicans
species infection. Because the susceptibilities to antifungal
agents were different between C. albicans and C. non-
albicans, the information about the difference in the clin-
ical risk factors between them may be useful to physicians
to guide the initial empirical treatment. Patients with C.
tropicalis IC had the highest rate of 30-day mortality,
whereas those with C. glabrata IC had the lowest mortality
rate. However, there is no evidence to show that higher
resistance rates among C. non-albicans species will be
related to the patient’s mortality.
Univariate analyses showed a significantly higher rate of
C. non-albicans spp. in IC patients with a long stay in hos-
pital, chemotherapy, hematologic malignancy, neu-
tropenia, long-term use of corticosteroids, and usage of
glycopeptides, whereas C. albicans infection was more
likely associated with older age, solid tumor, and hypo-
proteinemia. Other published studies reported that C. non-
albicans spp. had been associated with hematologic ma-
lignancy, neutropenia, allogenic stem cell transplantation,
prior fluconazole prophylaxis, and chemotherapy.12,21e23
Multivariate analyses showed that hypoproteinemia was a
significant predictor for patients with IC due to C. albicans.
A long-term study carried out in China showed that hypo-
proteinemia, endotracheal intubation, and the presence of
C. albicans were found to predict rapid mortality inde-
pendently.24 Compared with other Candida species, C.
albicans has been found to be more likely to inhabit the
human gastrointestinal tract.25 In addition, hypo-
proteinemia is always associated with surgical site infection
in patients undergoing general surgery procedures.26
Therefore, it can be hypothesized that hypoproteinemia
caused by gastrointestinal tract surgery and the related
infection may finally result in C. albicans infection.
The limitations of this study must be stressed. The major
one is a definitive conclusion could not be made because of
insufficient number of cases. Besides, the risk factors
investigated in this study may not be comprehensive and
did not include some risk factors assessed in other studies.
Furthermore, minimum inhibitory concentration of echi-
nocandins, which are important antifungal agents againstl susceptibilities, and risk factors for invasive candidiasis from 2011
gy, Immunology and Infection (2015), http://dx.doi.org/10.1016/
Table 3 Characteristics of Candida albicans and Candida non-albicans in normally sterile site infection cases
Variables C. albicans
(n Z 125)
C. non-albicans
(n Z 132)
p
n (%) n (%)
Male sex 84 (67.2) 86 (65.2) 0.729
Elderly (60 y) 81 (64.8) 64 (48.5) 0.008*
Hospital stay, d 10 (2e20) 15 (5e32) 0.005*
ICU stay 74 (59.2) 70 (53.0) 0.319
Length of ICU stay, d 1 (0e5) 1 (0e12) 0.480
Corticosteroids 29 (23.2) 50 (37.9) 0.011*
Duration on corticosteroids, d 0 (0e0) 0 (0e1) 0.005*
Immunosuppressive agents 3 (2.4) 2 (1.5) 0.677
Chemotherapy 3 (2.4) 12 (9.1) 0.022*
30-d mortality 10 (8.0) 15 (11.4) 0.363
All-cause in-hospital mortality 17 (13.6) 20 (15.2) 0.723
Patient source
Gastrointestinal surgery 22 (17.6) 18 (13.6) 0.381
Hepatobiliary surgery 13 (10.4) 13 (9.8) 0.883
Urinary surgery 8 (6.4) 7 (5.3) 0.708
Neurosurgery 3 (2.4) 10 (7.6) 0.058
Invasive procedures within prior 4 wk
Blood product transfusion 63 (50.4) 65 (49.2) 0.853
Hemodialysis 4 (3.2) 7 (5.3) 0.405
Mechanical ventilation 57 (45.6) 46 (34.8) 0.079
Tracheal intubation 49 (39.2) 37 (28.0) 0.058
Indwelling gastric tube 77 (61.6) 70 (53.0) 0.165
Urinary catheter 97 (77.6) 92 (69.7) 0.151
Drainage tube 84 (67.2) 75 (56.8) 0.087
Enema 55 (44.0) 44 (33.3) 0.079
Total parental nutrition 10 (8.0) 17 (12.9) 0.202
Arterial catheter 41 (32.8) 59 (44.7) 0.051
Central venous catheter 63 (50.4) 77 (58.3) 0.202
Surgery 84 (67.2) 77 (58.3) 0.142
Underlying condition
Diabetes mellitus 22 (17.6) 29 (22.0) 0.380
Organ dysfunction 22 (17.6) 17 (12.9) 0.292
Solid tumor 28 (22.4) 16 (12.1) 0.029*
Hematologic malignancy 2 (1.6) 9 (6.8) 0.039*
Hypoproteinemia 98 (78.4) 86 (65.2) 0.019*
Severe anemia 11 (8.8) 12 (9.1) 0.935
Neutropenia 0 (0.0) 6 (4.5) 0.030*
Antibiotic therapy
b-Lactams 40 (32.0) 55 (41.7) 0.109
Cephalosporins 92 (73.6) 82 (62.1) 0.049*
Carbapenems 50 (40.0) 63 (47.7) 0.212
Aminoglycosides 30 (24.0) 43 (32.6) 0.128
Quinolones 24 (19.2) 32 (24.2) 0.328
Glycopeptides 22 (17.6) 46 (34.8) 0.002*
Nitroimidazoles 61 (48.8) 58 (43.9) 0.435
Data are expressed no. (%) of patients or median and interquartile range unless otherwise indicated.
ICU Z intensive care unit.
*p was statistically significant.
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+ MODELazole-resistant Candida species (e.g., C. glabrata), was not
investigated here. We will address these limitations in our
future work.
In conclusion, this study showed the epidemiology and
antifungal susceptibilities of invasive Candida species iso-
lated from the First Affiliated Hospital of Chongqing MedicalPlease cite this article in press as: Pu S, et al., Epidemiology, antifunga
to 2013 in a teaching hospital in southwest China, Journal of Microbiolo
j.jmii.2015.01.005University between 2011 and 2013, and the difference in
risk factors between C. albicans and C. non-albicans spe-
cies. C. albicans was the most common species, compared
with the C. non-albicans species. C. albicans, C. tropicalis,
and C. parapsilosis had a high susceptibility to the five
antifungal agents, whereas C. glabrata showed decreasedl susceptibilities, and risk factors for invasive candidiasis from 2011
gy, Immunology and Infection (2015), http://dx.doi.org/10.1016/
Table 4 Multivariate logistic regression analyses of risk
factors associated with Candida albicans infections
Variables OR 95% CI p
Lower Upper
Elderly (60 y) 1.423 0.818 2.476 0.212
Hospital length of
stay
0.991 0.977 1.005 0.211
Corticosteroids 0.857 0.428 1.715 0.633
Duration on
corticosteroids
0.94 0.84 1.052 0.280
Chemotherapy 0.422 0.079 2.242 0.311
Solid tumor 1.791 0.862 3.72 0.118
Hematologic
malignancy
3.345 0.342 32.744 0.300
Hypoproteinemia 2.133 1.164 3.908 0.014*
Neutropenia 0 0 d 0.999
Glycopeptides 0.526 0.268 1.031 0.061
CI Z confidence interval; OR Z odds ratio.
*p was statistically significant.
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icin B is highly effective in vitro against all Candida species.
We differentiated several clinical risk factors for IC due to
C. albicans (older age, solid tumor, and hypoproteinemia)
and C. non-albicans spp. (long stay in hospital, chemo-
therapy, hematologic malignancy, neutropenia, long-term
use of corticosteroids, and usage of glycopeptides).
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